Thioacetazone (Thiacetazone)

A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217)

Also Known As:

Networked: 251 relevant articles (9 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ndiaye, B: 2 articles (12/2001 - 01/2001)
2.	Gopal, Pooja: 1 article (04/2015)
3.	Dick, Thomas: 1 article (04/2015)
4.	Falzon, Dennis: 1 article (12/2014)
5.	Jaramillo, Ernesto: 1 article (12/2014)
6.	Suwankesawong, Wimon: 1 article (12/2014)
7.	Pal, Shanthi N: 1 article (12/2014)
8.	Hill, Geraldine: 1 article (12/2014)
9.	Qureshi, Danish: 1 article (04/2014)
10.	Dixit, Ramakant: 1 article (04/2014)

Related Diseases

1.	Pulmonary Tuberculosis 01/01/2007 - "[A case of multidrug-resistant pulmonary tuberculosis cured by the regimen including thiacetazone]." 10/01/1999 - "In order to develop a local policy concerning the use of this drug, a study was undertaken to determine the incidence of such reactions in a total of 1063 Ghanaian adult patients treated for pulmonary tuberculosis (PTB) with thiacetazone-containing regimens. " 02/01/1952 - "[Studies on blood sedimentation, and its value as an indicator of activity, in conteben therapy of pulmonary tuberculosis]." 02/01/1998 - "Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon." 08/01/1997 - "A prospective study of 235 consecutive pulmonary tuberculosis (TB) patients admitted to Hospital Jamot in Yaounde, Cameroon, in a 6-month period in 1994 investigated the HIV seroprevalence in these patients and compared the incidence of adverse skin reactions in HIV-positive and HIV-negative patients receiving thiacetazone-free anti-TB treatment. "
2.	Tuberculosis (Tuberculoses) 05/01/1993 - "The results of this study were in part responsible for the recommendations put forward by the World Health Organization to avoid the use of thiacetazone in the treatment of tuberculosis in children infected with HIV." 08/01/1983 - "[Experimental study of thiacetazone in the treatment of tuberculosis. " 01/01/1952 - "[The relation of in vitro conteben sensitivity to conteben therapy; a study on conteben resistant tuberculosis strains]." 04/01/2015 - "The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone." 12/01/2014 - "Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone."
3.	Infection 09/09/1995 - " Case fatality from adverse cutaneous reactions was considerably less frequent than previously reported, suggesting that improved management may allow the retention of thiacetazone as a weapon against TB even where infection with HIV is prevalent." 02/01/1996 - "Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection." 01/01/1980 - "In this study we assess the degree of prolonged bacteriostasis of Mycobacterium leprae after temporary exposure to ehtionamide or thiacetazone, and relate this to their efficacy when administered intermittently to mice with experimental leprosy infections. " 09/09/1995 - "Case fatality from adverse cutaneous reactions was considerably less frequent than reported previously, suggesting that improved management might allow retention of thiacetazone in the armamentarium of national tuberculosis programmes even where infection with HIV is prevalent. " 04/01/1994 - "Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen."
4.	Leprosy (Hansen's Disease) 10/01/1959 - "The value of thiacetazone (TB-1) in leprosy." 04/01/1953 - "[Conteben in the treatment of leprosy]." 10/01/1952 - "[Therapy of leprosy with conteben]." 10/01/1951 - "The treatment of leprosy with conteben." 05/01/1959 - "[Synergistic treatment of Hansen's disease by bimonthly injections of diaminodiphenyl-sulfone-thioacetazone in a chaulmoogra medium]."
5.	Laryngeal Tuberculosis 04/01/1953 - "[Symptom remission and recovery in laryngeal tuberculosis after conteben therapy]." 03/01/1951 - "[Blood perfusion of the pharyngeal mucosa as an aid in the diagnosis and prognosis of pulmonary and laryngeal tuberculosis, and in the evaluation of conteben therapy]." 01/05/1951 - "[Experiences with conteben in the treatment of laryngeal tuberculosis]." 01/01/1951 - "[Bayer's TB I/698 in the treatment of laryngeal tuberculosis]." 01/01/1950 - "[Tuberculosis and thiosemicarbazone Tb I/698; therapeutic results in pulmonary and secondary laryngeal tuberculosis]."

Related Drugs and Biologics

1.	Isoniazid (Ftivazide)
2.	Streptomycin (Streptomycin Sulfate)
3.	Rifampin (Rifampicin)
4.	Pyrazinamide
5.	cytochalasin E
6.	geldanamycin
7.	Thioacetazone (Thiacetazone)
8.	Ethambutol (Myambutol)
9.	Ethionamide (Trecator-SC)
10.	Aminosalicylic Acid (Rezipas)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Injections
4.	Aftercare (After-Treatment)